TheAnswerPage launches cannabis CME course for clinicians

By AI, Created 10:00 AM UTC, May 20, 2026, /AGP/ – TheAnswerPage.com has launched a new 4-credit CME/CE course on cannabis and cannabinoids as medical cannabis rescheduling raises patient interest and demand for clinical guidance. The program is aimed at helping clinicians in multiple specialties improve evidence-based counseling, safety screening and management of cannabis-related conditions.

Why it matters: - Medical cannabis rescheduling is expected to increase patient interest, product use and demand for clinician guidance. - Clinicians across specialties are seeing more patients who use cannabis-based products, but many have not had enough training on pharmacology, safety, interactions and practical care. - The course is aimed at improving evidence-based counseling and reducing the gap between patient use and clinician knowledge.

What happened: - TheAnswerPage.com launched a new flagship 4-credit CME/CE course, Cannabis and Cannabinoids in Clinical Practice, on May 4, 2026. - The course is available now at TheAnswerPage.com. - TheAnswerPage.com also launched a separate 2-credit CME/CE course on Cannabis Use Disorder and Cannabinoid Hyperemesis Syndrome on May 5, 2026.

The details: - The course is designed for physicians, nurses, nurse practitioners, pharmacists, physician assistants and other healthcare professionals. - The curriculum is split into two integrated sections: How Cannabis Works in the Body and Clinical Effects and Therapeutic Use of Cannabis. - The first section covers the endocannabinoid system, cannabinoid pharmacology, routes of administration, pharmacokinetics, product variability and clinically relevant drug interactions. - The second section reviews cannabis effects across major organ systems, therapeutic evidence for commonly cited conditions, use in high-risk populations and clinical complications such as cannabis use disorder and cannabinoid hyperemesis syndrome. - The activity emphasizes critical appraisal of evidence so clinicians can distinguish high-quality data from marketing claims, anecdote and misinformation. - The course is meant to help clinicians communicate more effectively with patients and provide balanced, evidence-based guidance. - The program is especially relevant to primary care, emergency medicine, anesthesia, psychiatry, neurology, oncology, cardiology, gastroenterology, geriatrics, pediatrics, obstetrics and gynecology, and pharmacy practice. - TheAnswerPage.com has provided required or state-aligned cannabis education in multiple U.S. jurisdictions for more than a decade.

Between the lines: - The launch reflects a broader shift in medical cannabis from a niche topic to a routine clinical issue that crosses specialties. - The emphasis on evidence review suggests the company is positioning the course as a response to misinformation, uneven training and fast-changing regulation. - Stephen B. Corn, MD said the recent rescheduling will likely accelerate demand for guidance and that clinicians need balanced education now more than ever. - Meredith Fisher-Corn, MD said patients are already making decisions involving cannabis with incomplete or inaccurate information and that clinicians need to interpret evidence objectively and identify harms and benefits.

What’s next: - Clinicians who want training can enroll in the new 4-credit course now. - Healthcare professionals needing focused education on cannabis-related disorders can also access the new 2-credit CUD and CHS course. - TheAnswerPage.com says it will continue working with health departments, medical associations, hospital systems and other healthcare organizations as educational needs evolve.

The bottom line: - Cannabis education is moving from optional background knowledge to practical clinical necessity as more patients use cannabis and ask their clinicians for guidance.